Ep. 84: Austin Lieberman: Why Investors Shouldn't Be Afraid Of Expensive Stocks
Investing With IBD
00:00
The Competition in the Bio Life Space
The company is a serial acquirer of other businesses to grow their capabilities, which can be good if they've done well. The stock's actually up about a thousand percent over the last, I think it's over the last five years. Selgene is a customer, CRISPR is a customers, Ettotas is a customer,. Novartis, Kite Pharma, looking for stocks that have outperformed and continue to outperform.
Transcript
Play full episode
